# Kairos Pharma Ltd. (KAPA)

Source: https://www.quantisnow.com/company/KAPA
Generated: 2026-11-13T12:15:46.749Z

- Ticker: KAPA
- Exchange: AMEX
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2024
- SEC CIK: 0001962011

## Latest KAPA news and filings

- 2026-11-05 14:15 UTC [SEC Form 8-K] [Kairos Pharma Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kairos-pharma-ltd-filed-sec-form-8-k-other-events-financial-6775213)
- 2026-11-05 14:15 UTC [Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology](https://www.quantisnow.com/insight/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology-6775203)
- 2026-11-03 16:50 UTC [SEC Form 8-K] [Kairos Pharma Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kairos-pharma-ltd-filed-sec-form-8-k-entry-into-a-6769064)
- 2026-11-03 16:45 UTC [Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development](https://www.quantisnow.com/insight/kairos-pharma-presents-at-united-scientific-groups-11th-international-conference-6769059)
- 2026-10-06 11:30 UTC [SEC Form 8-K] [SEC Form 8-K filed by Kairos Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-kairos-pharma-ltd-6738115)
- 2026-10-06 11:30 UTC [Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer](https://www.quantisnow.com/insight/kairos-pharma-reports-positive-statistically-significant-interim-efficacy-data-from-6738093)
- 2026-09-23 12:00 UTC [Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA](https://www.quantisnow.com/insight/kairos-pharma-to-present-and-moderate-at-discovery-on-target-6723638)
- 2026-09-14 20:00 UTC [SEC Form 8-K] [Kairos Pharma Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kairos-pharma-ltd-filed-sec-form-8-k-regulation-fd-disclosure-6714360)
- 2026-09-09 12:00 UTC [Conference Announcement] [Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/kairos-pharma-to-present-at-the-hc-wainwright-28th-annual-6709274)
- 2026-08-21 20:30 UTC [SEC Form 8-K] [Kairos Pharma Ltd. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure](https://www.quantisnow.com/insight/kairos-pharma-ltd-filed-sec-form-8-k-material-modification-to-6691479)
- 2026-08-21 20:30 UTC [Kairos Pharma Announces 1-for-7 Reverse Stock Split](https://www.quantisnow.com/insight/kairos-pharma-announces-1-for-7-reverse-stock-split-6691456)
- 2026-08-12 20:10 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Kairos Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-kairos-pharma-ltd-6677931)
- 2026-07-22 12:35 UTC [SEC Form 8-K] [Kairos Pharma Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kairos-pharma-ltd-filed-sec-form-8-k-entry-into-a-6644798)
- 2026-07-22 12:35 UTC [Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer](https://www.quantisnow.com/insight/kairos-pharma-announces-strategic-collaboration-with-bayer-to-enhance-xofigo-6644795)
- 2026-07-15 12:30 UTC [SEC Form 8-K] [Kairos Pharma Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kairos-pharma-ltd-filed-sec-form-8-k-other-events-financial-6637724)
- 2026-06-30 21:19 UTC [SEC Form 8-K] [SEC Form 8-K filed by Kairos Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-kairos-pharma-ltd-6621288)
- 2026-06-04 12:00 UTC [SEC Form 8-K] [Kairos Pharma Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kairos-pharma-ltd-filed-sec-form-8-k-other-events-financial-6588631)
- 2026-05-26 21:24 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Kairos Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-kairos-pharma-ltd-6573056)
- 2026-05-22 20:10 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Kairos Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-kairos-pharma-ltd-6569735)
- 2026-05-18 12:31 UTC [SEC Form 8-K] [Kairos Pharma Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kairos-pharma-ltd-filed-sec-form-8-k-other-events-financial-6559323)
- 2026-05-14 12:00 UTC [Kairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical Award](https://www.quantisnow.com/insight/kairos-pharma-receives-ghp-magazines-healthcare-pharmaceutical-award-6552467)
- 2026-05-13 21:20 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Kairos Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-kairos-pharma-ltd-6551704)
- 2026-05-11 18:05 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Kairos Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-kairos-pharma-ltd-6544458)
- 2026-05-08 20:30 UTC [Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings](https://www.quantisnow.com/insight/kairos-pharma-ltd-sets-annual-meeting-of-shareholder-date-and-6542434)
- 2026-04-15 13:00 UTC [Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation](https://www.quantisnow.com/insight/kairos-pharma-recognized-with-pinnacle-award-for-excellence-in-healthcare-6500732)
- 2026-04-01 20:50 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kairos Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kairos-pharma-ltd-6482446)
- 2026-04-01 20:50 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kairos Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kairos-pharma-ltd-6482445)
- 2026-03-31 20:10 UTC [SEC Form 10-K] [SEC Form 10-K filed by Kairos Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-kairos-pharma-ltd-6479143)
- 2026-03-02 11:31 UTC [SEC Form 8-K] [Kairos Pharma Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kairos-pharma-ltd-filed-sec-form-8-k-entry-into-a-6420557)
- 2026-03-02 11:30 UTC [Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics](https://www.quantisnow.com/insight/kairos-pharma-announces-signing-of-binding-strategic-asset-acquisition-of-6420544)
- 2026-02-26 12:00 UTC [SEC Form 8-K] [Kairos Pharma Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kairos-pharma-ltd-filed-sec-form-8-k-other-events-financial-6414747)
- 2026-02-26 12:00 UTC [Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics](https://www.quantisnow.com/insight/kairos-pharma-ltd-announces-signing-of-term-sheet-for-strategic-6414724)
- 2026-01-26 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Kairos Pharma Ltd.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-kairos-pharma-ltd-6359907)
- 2026-01-23 19:50 UTC [Market Insight] [DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event](https://www.quantisnow.com/insight/dealflow-discovery-conference-announces-initial-lineup-of-presenting-companies-ahead-6359020)
- 2026-01-20 13:00 UTC [Conference Announcement] [Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference](https://www.quantisnow.com/insight/kairos-pharma-to-present-at-3rd-annual-dealflow-discovery-conference-6353291)
- 2025-12-30 21:10 UTC [SEC Form 4] [Chief Scientific Officer Bhowmick Neil was granted 171,756 shares, increasing direct ownership by 15% to 1,311,739 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-bhowmick-neil-was-granted-171756-shares-increasing-6329910)
- 2025-12-23 11:03 UTC [SEC Form 4] [Director Bae Hyun W. was granted 29,084 shares, increasing direct ownership by 66% to 73,370 units (SEC Form 4)](https://www.quantisnow.com/insight/director-bae-hyun-w-was-granted-29084-shares-increasing-direct-6326108)
- 2025-12-17 13:15 UTC [Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer](https://www.quantisnow.com/insight/kairos-pharma-wins-2025-clinical-trials-arena-research-and-development-6319177)
- 2025-11-26 23:50 UTC [SEC Form 4] [VP of Research and Development Murali Ramachandran was granted 152,672 shares, increasing direct ownership by 104% to 299,529 units (SEC Form 4)](https://www.quantisnow.com/insight/vp-of-research-and-development-murali-ramachandran-was-granted-152672-6295740)
- 2025-11-26 22:27 UTC [SEC Form 4] [Director Keyoung Hansoo Michael was granted 29,084 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-keyoung-hansoo-michael-was-granted-29084-shares-sec-form-6295634)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/KAPA
- Earnings history: https://www.quantisnow.com/earnings/KAPA
- Dividend history: https://www.quantisnow.com/dividends/KAPA
- Insider transactions: https://www.quantisnow.com/insiders/KAPA
- Options chain: https://www.quantisnow.com/options/KAPA
- SEC 8-K filings only: https://www.quantisnow.com/company/KAPA/8-k
- RSS and alerts for KAPA: https://www.quantisnow.com/docs/rss-feeds.md